Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Stock Up 1.8 %

Evogene stock opened at $1.46 on Tuesday. Evogene has a 52 week low of $1.20 and a 52 week high of $9.00. The stock has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.94. The company has a market capitalization of $7.81 million, a price-to-earnings ratio of -0.33 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.72) by $0.78. The business had revenue of $1.61 million for the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same period in the prior year, the firm earned ($1.30) EPS.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.